Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Bp1001 In Combination With Ldac

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT01159028Phase 1Completed

Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS

Showing all 1 trials

Research Network

Common Treatments

  • Bp1001 In Combination With Ldac1
  • Bp10011

Active Sponsors

  • Bio-Path Holdings, Inc.1

Top Investigators

Related Conditions

  • Recurrent Adult Acute Myeloid Leukemia1
  • Acute Lymphoblastic Leukemia1
  • Myelodysplastic Syndrome1

Activity Timeline